Identifying biomarkers for detecting hidden cancer in patients with blood clots

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify novel biomarkers that can help detect occult cancer in patients diagnosed with venous thromboembolism (VTE). It focuses on understanding the relationship between inflammation, hypercoagulability, and cancer, particularly through the study of neutrophil extracellular traps (NETs). By improving risk prediction models, the study seeks to determine which VTE patients may benefit from more extensive cancer screening. The research is conducted at Danderyd Hospital and Södersjukhuset in Stockholm.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography;
* \> 18 years or older;
* Written informed consent

Exclusion Criteria:

* \> 2 days after VTE diagnosis;
* No blood withdrawal at baseline

Where it's running

• Danderyd Hospital
  Stockholm, Sweden Recruiting
• Södersjukhuset
  Stockholm, Sweden Recruiting

Study contacts

• Principal investigator: Charlotte Thålin, M.D., Ph.D. — Karolinska Institutet
• Study coordinator: Charlotte Thålin, M.D., Ph.D.
• Email: charlotte.thalin@sll.se
• Phone: +46709565120

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DoACs vs LMWH for blood flow after knee replacement

  This study tests whether rivaroxaban, apixaban, or LMWH work differently to support blood flow in the legs after total knee replacement in adults.

  Recruiting Military Hospital of Tunis · Tunis, Tunis Governorate · NCT07869615

• Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE

  This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.

  Recruiting Marmara University Pendik Training and Research Hospital · Istanbul · NCT07805616

• Screening for blood clots in adults with acute heart failure

  This trial tests whether a guideline-based screening approach can detect pulmonary embolism in adults admitted with acute heart failure.

  Recruiting University Hospital, Angers · Agen and 9 other locations · NCT07499661

• Blood test and software to guide treatment for venous thromboembolism

  This project tests whether a blood-based ctDNA test combined with a software risk score can predict if VTE will come back in adults with cancer-associated DVT or PE who have finished 3–12 months of anticoagulation.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07399977

• Aspiration thrombectomy with the Symphony or Prodigy devices

  This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.

  Recruiting at 13 sites Imperative Care, Inc. · Huntsville, Alabama and 12 other locations · NCT07350499

• Combining European cohort data to find biomarkers that guide treatment for venous thromboembolism

  This project combines clinical, biological and imaging data from European patient cohorts to try to find biomarkers that predict clot recurrence, bleeding, or death in people with venous thromboembolism.

  Recruiting University Hospital, Brest · Brest · NCT07328152

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.